# Procuring HIV Diagnostic Tools Manufacturers, implementers and agencies

# Market share of HIV RDT products 31 January 2012

Presented by Birgit Fleurent Consultant





















#### **Objective**

- Provide a market analysis of procurement data for HIV Rapid Diagnostic tests (RDTs)
  - By country
  - By manufacturer
  - By product
- Scope and Method
  - Analysis of HIV RDT procurement 2009 2011
  - Data sources included:
    - Global Fund (GF) Price and Quality reporting Mechanism (PQR)
    - WHO Global Price Reporting Mechanism (GPRM)
      - Focus on Global Fund PQR in 2010-2011














#### Total \$US and volume of HIV RDTs Procurement reported to Global Fund and WHO GPRM



















# Analysis of HIV RDT reported purchases to GF PQR and WHO GPRM

- Total number of HIV RDTs ranged from 80 million tests in 2009 dropping to 12 million tests in 2011
  - WHO GPRM data for 2011 shows \$8.7 million revenue but no corresponding test numbers
    - Assuming an ASP of \$0.95, # of tests for 2011 can be estimated at \$8.2 million, bringing 2011 total # of tests to 20 million
  - Global Fund PQR data for 2009 shows 54% of tests reported procured were from India at a price of \$0.31/Test
    - Subsequent years do not reflect the same procurement levels for India
- Focus of this analysis on 2010-2011, with implementation of Global Fund Quality Assurance Policy for Diagnostics















#### HIV RDTs 2010-2011 Top 7 countries in reported purchases to GF



# HIV RDTs 2010-2011 Top 7 Manufacturers in reported purchases to GF

















# HIV RDTs 2010-2011 Top 7 Products in reported purchases to GF















#### Analysis of HIV RDT reported purchases to Global Fund PQR

- Top 3 HIV procured RDTs in 2010-2011 were:
  - Determine HIV-1/2 and Determine HIV-1/2 WB test by Inverness (Alere) (also sold by Orgenics)
  - SD Bioline HIV-1/2 3.0 by Standard Diagnostics
  - Diagnostic Kit for HIV by Shanghai Kehua
- HIV RDT median price per test ranges from \$1.08 in 2010 to \$1.07 in 2011











#### Analysis of HIV RDT reported purchases to Global Fund PQR

- 45% of HIV RDTs procured in 2010 are now WHO prequalified
- 74% of HIV RDTs procured in 2010 have entered the WHO prequalification process or are prequalified
- 75% of HIV RDTs procured in 2011 are now WHO prequalified
- 78% of HIV RDTs procured in 2011 have entered the WHO prequalification process or are prequalified











#### **Final remarks**

- Improvements to the PQR have resulted in more accurate reporting of procurement by Grantees, helping to monitor compliance with the policy and market trends
- Since the policy has been implemented, all reported HIV RDTs to the PQR have met the criteria of the Global Fund QA policy
- An increasing number of HIV RDTs are WHO prequalified or under review for prequalification







